

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5517017

| | |
|---|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| TINA GJONI | 05/07/2019 |
| DUBRAVKA STRAZIC | 05/07/2019 |
| RECEIVING PARTY DATA | |
| Name: | XELLIA PHARMACEUTICALS APS |
| Street Address: | DALSLANDSGATE 11 |
| City: | COPENHAGEN S |
| State/Country: | DENMARK |
| Postal Code: | DK-2300 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 16343443 |
| CORRESPONDENCE DATA | |
| Fax Number: | (860)286-0115 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 8602862929 |
| Email: | usptopatentmail@cantorcolburn.com,jboya@cantorcolburn.com |
| Correspondent Name: | CANTOR COLBURN LLP |
| Address Line 1: | 20 CHURCH STREET |
| Address Line 2: | 22ND FLOOR |
| Address Line 4: | HARTFORD, CONNECTICUT 06103 |
| ATTORNEY DOCKET NUMBER: | OSA0042US |
| NAME OF SUBMITTER: | KAREN A. LECUYER |
| SIGNATURE: | /Karen A. LeCuyer/ |
| DATE SIGNED: | 05/10/2019 |
| Total Attachments: 2 | |
| source=8AU5781#page1.tif | |
| source=8AU5781#page2.tif | |

OSA0042US (25712USPC)

DECLARATION AND ASSIGNMENT

Title of Invention: LIQUID FORMULATIONS OF DAPTOMYCIN

As a below named inventor, I hereby declare that:

This declaration is directed to:

- The attached application (Attorney Docket Number OSA0042US (25712USPC), or
- Patent application number U.S. 16/343,443, filed on 4/19/2019
- which is a 371 of PCT/EP2017/076519, filed 10/17/2017, which claims priority to US 62/411,024, filed 10-21-2016.

The above-identified application was made or authorized to be made by me, and I have reviewed and understand the contents of the application, including the claims.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I am aware of the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR Section 1.56.


Whereas, each undersigned inventor has made certain inventions, improvements, and discoveries (herein referred to as the "INVENTION") disclosed in the above-identified patent application (herein referred to as the "APPLICATION");



Whereas, XELLIA PHARMACEUTICALS APS, a corporation established in the Country of Denmark, with an office at or having a place of business at Dalslandsgade 11, Copenhagen S, Denmark DK-2300, (herein referred to as "ASSIGNEE"), desires to acquire or has acquired, and each undersigned inventor acknowledges the obligation to assign to ASSIGNEE, and the parties desire to use this Declaration and Assignment to memorialize the grant to ASSIGNEE of the entire worldwide right, title, and interest in and to the INVENTION including all embodiments thereof, and in and to any and all patent applications and patents directed thereto;

Now, therefore, for good and valuable consideration, the receipt and sufficiency thereof being hereby acknowledged, each undersigned inventor (herein referred to as "ASSIGNOR") hereby sells or has sold, assigns or has assigned, and otherwise transfers or has transferred to the ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the INVENTION, the APPLICATION, and any and all other patent applications and patents for the INVENTION which may be applied for or granted therefor in any and all countries and jurisdictions, including all divisions, continuations, continuations-in-part, reissues, reexaminations, renewals, extensions, counterparts, substitutes, and extensions thereof, and all rights of priority resulting from the filing of such applications and granting of such patents. In addition, each undersigned inventor hereby authorizes and requests any official whose duty it is to issue patents, to issue any patent on said improvements or resulting therefrom to said ASSIGNEE, its successors, legal representatives, and assigns, the entire worldwide right, title, and interest in and to the same to be held and enjoyed by ASSIGNEE, its successors, legal representatives, and assigns to the full end of the terms for which any and all such patents may be granted, as fully and entirely as would have been held and enjoyed by the undersigned had this Assignment not been made; and each undersigned inventor agrees to execute any and all documents and instruments and perform all lawful acts reasonably related to recording this Assignment or perfecting title to the INVENTION, the APPLICATION, and all related patents and applications, in ASSIGNEE, its successors, legal representatives, and assigns, whenever requested by ASSIGNEE, its successors, legal representatives, and assigns.

Each undersigned inventor also hereby grants ASSIGNEE, its successors, legal representatives, and assigns, the right to insert in this Declaration and Assignment any further identification of the APPLICATION (including, but not limited to, patent Application Number and filing date, and Attorney Docket Number), and further grants ASSIGNEE, its successors, legal representatives, and assigns the right to execute confirmatory assignments on their behalf.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature:  Date: 07.05.2019.
Name of Inventor: TINA GRONI

Witness:  Date: 07.05.19 Witness:  Date: 07.05.2019

OSA0042US (25712USPC)




DECLARATION AND ASSIGNMENT

Title of Invention: LIQUID FORMULATIONS OF DAPTOMYCIN

As a below named inventor, I hereby declare that:

This declaration is directed to:

- The attached application (Attorney Docket Number OSA0042US (25712USPC), or
- Patent application number U.S. 16/343,443, filed on 4/19/2019
- which is a 371 of PCT/EP2017/076519, filed 10/17/2017, which claims priority to US 62/411,024, filed 10-21-2016.

Signature:  Date: 07.05.2019.
Name of Inventor: **DUBRAVKA STRAZIC**
Witness:  Date: 07/05/2019 Witness:  Date: 7.5.2019.